About GenOway
GenOway is a company based in Lyon (France) founded in 1999. GenOway has raised $11.55 million across 5 funding rounds from investors including Siparex, European Union and Eurostars. The company has 143 employees as of December 31, 2024. GenOway has completed 1 acquisition, including Axenis. GenOway offers products and services including Humanized Mice, Cell Lines, Knockout Models, and Customized Models. GenOway operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Biocytogen, among others.
- Headquarter Lyon, France
- Employees 143 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Genoway Sa
-
Annual Revenue
$22.92 M (USD)10.04as on Dec 31, 2024
-
Net Profit
$1.9 M (USD)16.79as on Dec 31, 2024
-
EBITDA
$110.77 K (USD)0as on Dec 31, 2024
-
Total Equity Funding
$11.55 M (USD)
in 5 rounds
-
Latest Funding Round
$280.38 K (USD), Grant
Jan 01, 2020
-
Investors
Siparex
& 5 more
-
Employee Count
143
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of GenOway
GenOway is a publicly listed company on the EURONEXT with ticker symbol ALGEN in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of GenOway
GenOway offers a comprehensive portfolio of products and services, including Humanized Mice, Cell Lines, Knockout Models, and Customized Models.
Genetically modified mice for in vivo efficacy and safety testing
Modified cell lines for tumor growth and mechanistic studies
Mice and rats with targeted gene knockouts for research purposes
Bespoke genetically modified models for specific scientific questions
People of GenOway
Unlock access to complete
Funding Insights of GenOway
GenOway has successfully raised a total of $11.55M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $280.38 thousand completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in GenOway
GenOway has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Siparex, European Union and Eurostars.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments are focused on growth stage companies.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for GenOway
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by GenOway
GenOway has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Axenis.
Investment portfolio details for GenOway
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Chimeric in-vivo mouse models for biomedical research are developed.
|
Locked | Locked | 2010 | Locked |
Complete acquisition details for GenOway
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - GenOway
Detailed financials for GenOway
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Genoway Comparisons
Peer comparison for GenOway
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of GenOway
GenOway operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Biocytogen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
Integrated solutions for next-generation antibody drug development are provided.
|
|
| Locked | Locked | Locked |
RNA-editing technologies are provided for precision medicine applications.
|
Detailed competitors of GenOway
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Genoway
Complete news archive for GenOway
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GenOway
GenOway was founded in 1999 and raised its 1st funding round 4 years after it was founded.
GenOway is headquartered in Lyon, France. It is registered at Lyon, Auvergne-rhone-alpes, France.
GenOway is a funded company, having raised a total of $11.55M across 5 funding rounds to date.
As of Dec 31, 2024, the latest employee count at GenOway is 143.
Annual revenue of GenOway is $22.92M as on Dec 31, 2024.
GenOway was founded in 1999 and is based in Lyon, France. Operations center on the biotechnology sector, where transgenic mouse and rat models, along with customized cell lines, are created using techniques such as homologous recombination, CRISPRCas, FLEX, TET, and IRES Rosa 26Hprt. Knockout genes and point mutations are incorporated to address needs in neuroscience, immunology, metabolism, cardiovascular disorders, and cancer research.
GenOway's top competitors include Sutro Biopharma, Biocytogen and Avidity Biosciences.
GenOway offers Humanized Mice, Cell Lines, Knockout Models, and Customized Models.
Yes, GenOway is publicly traded on EURONEXT under the ticker symbol ALGEN.
GenOway has made 1 acquisition, including Axenis.
GenOway has 6 investors. Key investors include Siparex, European Union, Eurostars, CDC Entreprises Innovation, and Dassault Developpement.
The ticker symbol of GenOway is ALGEN on EURONEXT.